CVE-2022-1519

Description

LRM does not restrict the types of files that can be uploaded to the affected product. A malicious actor can upload any file type, including executable code that allows for a remote code exploit.

Category

10.0
CVSS
Severity: Critical
CVSS 3.1 •
CVSS 2.0 •
EPSS 0.15%
Third-Party Advisory cisa.gov
Affected: Illumina NextSeq 550Dx
Affected: Illumina MiSeq Dx
Affected: Illumina NextSeq 500 Instrument
Affected: Illumina NextSeq 550 Instrument
Affected: Illumina MiSeq Instrument
Affected: Illumina iSeq 100 Instrument
Affected: Illumina MiniSeq Instrument
Published at:
Updated at:

References

Link Tags
https://www.cisa.gov/uscert/ics/advisories/icsa-22-153-02 third party advisory us government resource

Frequently Asked Questions

What is the severity of CVE-2022-1519?
CVE-2022-1519 has been scored as a critical severity vulnerability.
How to fix CVE-2022-1519?
To fix CVE-2022-1519, make sure you are using an up-to-date version of the affected component(s) by checking the vendor release notes. As for now, there are no other specific guidelines available.
Is CVE-2022-1519 being actively exploited in the wild?
As for now, there are no information to confirm that CVE-2022-1519 is being actively exploited. According to its EPSS score, there is a ~0% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
What software or system is affected by CVE-2022-1519?
CVE-2022-1519 affects Illumina NextSeq 550Dx, Illumina MiSeq Dx, Illumina NextSeq 500 Instrument, Illumina NextSeq 550 Instrument, Illumina MiSeq Instrument, Illumina iSeq 100 Instrument, Illumina MiniSeq Instrument.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.